Table 1 –
Population demographics–features of patients in three cohorts at presentation.
| Demographic | Botswana(n = 384) | South Africa(n = 475) | United States(n = 361,353) | P-value |
|---|---|---|---|---|
|
| ||||
| Median age (IQR) | 54 (44–65) | 54 (44–66) | 61 (51–70) | <0.0001 |
| Gender | ||||
| Female (%) | 378 (98.44%) | 468 (98.53%) | 358,367 (99.17%) | |
| Male (%) | 6 (1.56%) | 7 (1.47%) | 2986 (0.83%) | |
| HIV | ||||
| HIV-Infected (%) | 49 (12.76%) | 50 (10.52%) | N/A | <0.0001* |
| HIV-Uninfected (%) | 65 (16.93%) | 224 (47.16%) | N/A | |
| HIV-Unknown (%) | 270 (70.31%) | 201 (42.32%) | N/A | |
| Ethnicity | ||||
| White | 0 (0%) | 124 (26.11%) | 300,671 (83.20%) | <0.0001 |
| Black/multiracial | 384 (100%) | 276 (58.11%) | 41,365 (11.45%) | |
| Other | 0 (0%) | 75 (15.79%) | 19,317 (5.35%) | |
| Receptor status | ||||
| ER+ and/or PR+, HER2− | 132 (62.56%) | 276 (69.70%) | 180,604 (73.96%) | <0.001 |
| ER+ and/or PR+, HER2+ | 19 (9.00%) | 49 (12.37%) | 21,987 (9.00%) | |
| ER−/PR−/HER2+ | 15 (7.11%) | 26 (6.57%) | 9999 (4.09%) | |
| ER−/PR−/HER2− | 45 (21.33%) | 45 (11.36%) | 31,592 (12.94%) | |
| Stage† | ||||
| Early Stage | 18 (35.29%) | 190 (42.89%) | 261,414 (91.62%) | <0.001‡ |
| Stage I | 4 (7.84%) | 54 (12.19%) | 174,294 (61.09%) | |
| Stage II | 14 (27.45%) | 136 (30.70%) | 87,120 (30.53%) | |
| Advanced Stage | 33 (64.71%) | 253 (57.11%) | 23,903 (8.38%) | |
| Stage III | 33 (64.71%) | 216 (48.76%) | 20,274 (7.11%) | |
| Stage IV | 0 (0.00%)§ | 37 (8.35%) | 3629 (1.27%) | |
*
Comparison of Botswana and South Africa only.
†
Stage at diagnosis (pathologic stage in Botswana and clinical stage in South Africa and the United States).
‡
Comparison of early versus advanced stage by country.
§
Stage IV unreported in Botswana due to use of pathologic staging.